Had Nader not prematurely announced the agreement, and THEN
Had Nader not prematurely announced the agreement, and THEN the FDA came out with their anonymous letter that torpedoed the deal --
the deal would have been made.
It was clear that it was the FDA letter that squelched it.
Had he just shut up until it was signed, we would have gotten emergency approval there.
Let's give discredit where discredit is due. Nader's big mouth, tipping off Big Pharma and the shorts that there was about to be a big upward change -- and then the FDA's captive writer screwing us.
3
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The clock's ticking down to November 10, and eyes are peeled for Quarterhill's Q3 financial debrief. Why the fuss? Well, they’ve made quite a name for themselves in the Intelligent Transportation System (ITS) scene, tossing AI into the mix to boot. If you’re playing in this space—or just sneaking a peek to see where tech’s steering us next—you might want to dial...
Continue Reading
The New Era at Acuity Analytics Has Begun Isn't it something when a company decides to shake things up in such a daring way? Acuity Analytics just gave the financial sector a reason to sit up and pay attention. They've brought in Jon O'Donnell as the new Chief Executive Officer, a move that's got the city talking. O'Donnell is no rookie; he's a former IBM heavyweight and...
Continue Reading
SportsMed Physical Therapy Expands with New Clinic Well, here we are, talking about expansion. And not just any expansion—I'm talking about SportsMed Physical Therapy flexing its muscles in Jersey City Heights, boosting their count to 58 clinics scattered across New Jersey and Connecticut. It's like watching a network of care roots spreading deeper into the region, and...
Continue Reading
New Crosshairs on Coastal Financial Corporation Man, it's another day and yet another fiasco in the corporate world. Late-breaking news from the trenches alerts us that Coastal Financial Corporation is in the legal spotlight. Yeah, you heard me right. We're talking about NASDAQ:CCB, the darlings turned defendants courtesy of recent allegations that could rock their stock....
Continue Reading
A Solid Quarter for CVS Health CVS Health Corporation has once again turned heads with its third-quarter 2026 results. When you're pulling $108.4 billion in quarterly revenue, up 5.4% from last year, folks notice. Adjusted earnings hit $2.09 per share, climbing a respectable 30% from $1.60 the year before. The cherry on top? A big fat boost in 2026 guidance, signaling...
Continue Reading
A New Era for Family Entertainment Centers Forget the traditional FEC with its solitary rides; the future's all about constructing social destinations that blend immersive storytelling and hybrid offerings. Elephant Sculpture Art Co., Ltd. (ESAC) is at the forefront, drawing from their Shanghai WUNPARK project to reimagine the design of these amusement hubs. Set to engage...
Continue Reading
Zeelo's got itself a new captain steering its West Coast ship, and it’s none other than transportation whiz Gillian Zoss. Now, when a company like Zeelo pulls a move like this, it's worth taking a moment to chew over the implications. Zeelo's been known for shaking up how folks think about moving people—employees, kids to schools, you name it—their model's rattled a...
Continue Reading
Spotlight on Emerging Titans: The Future 100 Watchlist The Sovereign Wealth Fund Institute is rattling the investment cages with their latest stunt, the 'Future 100 Watchlist.' Hot off the press, this list is parading nearly 3,000 start-ups that are biting at the heels of future success. It's high stakes and higher hopes between December 11-16 at Miami's I20 Summit, where...
Continue Reading
Investors Find Gold in Broken Bow’s Airbnb Market When did Broken Bow, Oklahoma, become the go-to spot for adventurous investors looking to park their cash in timberland sanctuary cabins? Well, Cathy Craig seems to know the secret sauce, having navigated over $163 million worth of Airbnb and VRBO cabin deals for her clients since 2021. Her knack for spotting cabins that...
Continue Reading
Shake-Up in Investor Circles Over D&B Class Action Lemme tell ya, Dun & Bradstreet Holdings (NYSE:DNB)—that name is echoing through courtrooms these days. It's like watching an old time Wall Street brawler go a few rounds with a heavyweight. Investors better sit tight because we've got a class action cooked up, and the lead plaintiff deadline smacks us in the face on...
Continue Reading
Top 5 Most Recently Viewed Articles
Understanding Recent Insider Transactions at Tanger Inc. A noteworthy insider sell has surfaced recently, involving Joseph Thomas Guerrieri JR, who serves as Senior Vice President at Tanger (NYSE: SKT). The details of this transaction arose from a recent filing with the SEC, highlighting a substantial move by an insider. Transaction Overview: JR opted to divest 3,000...
Continue Reading
The Remarkable Growth of Charles Schwab Stock Over the past 20 years, Charles Schwab has consistently outperformed the overall market, showcasing a remarkable annualized return of 10.34%. This impressive performance has led to a market capitalization of approximately $141.73 billion. Understanding how this growth can translate for individual investors can provide valuable...
Continue Reading
Exciting New Community Opening in Tolleson Richmond American Homes is thrilled to announce the grand opening of the Seasons at Vista Del Sur community. This new development promises to be a welcoming place for families and individuals looking to settle in a vibrant environment. With an impressive range of single- and two-story homes, Richmond American is committed to...
Continue Reading
Rocket Lab Chosen for Groundbreaking NASA Mars Study Rocket Lab USA, Inc. (NASDAQ: RKLB) has an exciting opportunity in store as it embarks on a study for NASA's Mars Sample Return Program. This initiative is poised to be a historic endeavor, aiming to retrieve Martian rock samples and analyze them on Earth—offering unprecedented insights into Mars and the potential for...
Continue Reading
A Robust Quarter for ASE Technology Alright, sit down and buckle up because ASE Technology (NYSE: ASX) just dropped some eye-popping numbers for Q2 2026. This isn't some mild market fluctuation—this is what you call a serious win in the semiconductor game. With net revenues soaring to NT$191,064 million, it’s about 26.7% up from the same quarter last year. Now, that's...
Continue Reading